Health Canada has authorized Pfizer and BioNTech's XFG variant-adapted COMIRNATY vaccine for individuals aged six months and older, effective for the 2026-2027 COVID-19 season. The updated formulation targets the Omicron XFG lineage in alignment with public health recommendations to better match currently circulating variants. The authorization relies on cumulative clinical, non-clinical, and real-world evidence demonstrating the vaccine's safety and effectiveness. Built on BioNTech's proprietary mRNA technology, COMIRNATY represents the companies' ongoing commitment to evolving vaccine formulations as the virus mutates. Pfizer Canada has secured sufficient inventory to meet all contractual obligations with federal and provincial vaccination programs, with distribution beginning through various channels in the coming weeks. This approval highlights vaccination's continued importance as an effective tool for reducing serious COVID-19 illness risk amid ongoing viral evolution.

Long COVID, clinically termed post-acute sequelae of COVID-19 (PASC), is a multisystem condition characterized by persistent symptoms lasting more than three months after acute infection that cannot be attributed to alternative diagnoses. Affected individuals commonly experience fatigue, brain fog, muscle pain, breathlessness, post-exertional malaise, dizziness, and cardiac symptoms indicative of autonomic dysfunction. Data from Welltory reveals that users self-reporting Long COVID experience post-exertion crashes 2.6 times more frequently and wake unrefreshed 4.6 times more often than other users, despite comparable daily wellness scores. Notably, no single diagnostic test definitively confirms Long COVID; diagnosis relies on clinical symptomatology and timeline. Globally, an estimated 400 million individuals experience persistent Long COVID symptoms following SARS-CoV-2 infection. Researchers acknowledge that underlying pathological mechanisms remain incompletely understood, though the disease's heterogeneity suggests a multifactorial origin. This distinction from typical post-infection malaise underscores Long COVID's significant impact on physiological regulation systems including energy, cognition, respiration, cardiac function, sleep, and activity tolerance.

Vaccination remains one of the most effective public health interventions for preventing infectious diseases, yet persistent challenges including hesitancy, delayed uptake, unequal access and incomplete immunization coverage continue to undermine vaccination programmes globally. While digital platforms and social media increasingly influence how people obtain and evaluate health information, enabling misinformation and polarized discourse to proliferate, vaccination gaps stem from multifactorial determinants extending beyond information exposure alone. Organizational and logistical barriers, socioeconomic deprivation, geographic inequality, health literacy levels, healthcare access and prior health service experiences significantly impact vaccination decision-making and completion. Recent research demonstrates the interconnected nature of these determinants across different populations and vaccination contexts, yet critical gaps remain in understanding how digital, social, psychological and structural factors combine to influence vaccination outcomes. This research initiative aims to advance knowledge of vaccine hesitancy, access and uptake determinants by examining digital information environments, healthcare barriers, and social, psychological, cultural and socioeconomic influences. It seeks to identify missed opportunities, explain inequities and generate evidence supporting effective public health education, communication strategies and equitable vaccination programmes across all life stages.

# Summary A peer-reviewed study published in Scientific Reports examined peripheral blood immune profiles in a specific population cohort, finding no statistically significant differences in immune cell composition or function between comparison groups. The research utilized flow cytometry and immunophenotyping techniques to analyze lymphocyte subsets, including T cells, B cells, and natural killer cells, across multiple participants. Despite systematic investigation of various immune markers, the analysis revealed comparable immune status across the examined populations, suggesting that peripheral blood immune parameters alone may not distinguish between the studied groups. This finding carries important implications for immunological research and clinical diagnostics, indicating that observable differences between populations—if present—likely involve tissue-specific immune responses or systemic factors beyond standard peripheral blood assessment. The results underscore the complexity of immune system evaluation and suggest that comprehensive immune profiling may require more sophisticated methodologies or examination of alternate biological compartments to detect clinically meaningful differences.

Researchers at the University of East Anglia and Oxford BioDynamics have discovered a potential biological unifying theory explaining why chronic fatigue occurs across seemingly unrelated conditions including long Covid, ME/CFS, PTSD, rheumatoid arthritis, and multiple sclerosis. Published in the Journal of Translational Medicine, the study reveals striking biological similarities among these five disorders, despite their distinct triggering mechanisms—ranging from viral infection and psychological trauma to autoimmune dysfunction. All share common symptoms including profound exhaustion, brain fog, concentration difficulties, and autonomic dysfunction. Rather than examining DNA as linear sequences, researchers employed Oxford BioDynamics' EpiSwitch® Orion platform to analyze three-dimensional genome organization, investigating how DNA folding patterns influence gene activity across distant genomic regions. This computational analysis combined previously published genomic data from genome-wide association studies with existing three-dimensional genomic information. The findings suggest these conditions may disrupt identical underlying biological systems, potentially revolutionizing treatment approaches by identifying common therapeutic targets rather than managing each condition separately.

The Prison Policy Initiative has compiled a comprehensive research collection examining how the criminal justice system affects population health and mortality outcomes. This curated resource aggregates existing research demonstrating the health consequences of incarceration and justice system involvement. The initiative recognizes that criminal justice policies have significant public health implications beyond traditional legal frameworks. The compilation serves researchers, policymakers, and advocates seeking evidence-based understanding of this intersection. The Prison Policy Initiative supplements this broader collection with original research available on their dedicated Health page, providing primary data and analysis on justice-related health impacts. The initiative positions this health-focused research within their broader Research Library, which addresses multiple criminal justice topics. By centralizing this specialized research, the initiative aims to inform policy discussions and highlight the healthcare implications of incarceration, contributing to a more comprehensive understanding of how the justice system influences population health outcomes and mortality rates across affected communities.

The Infectious Diseases Society of America has released comprehensive guidelines for treating and managing COVID-19 patients, emphasizing that disease severity assessment must precede all therapeutic decisions. The guidelines introduce a clinical decision aid to help prescribers identify appropriate treatment options for ambulatory patients by first establishing baseline risk for severe outcomes, including hospitalization, ventilation requirements, ICU admission, or death. The panel categorizes patients into risk stratifications using two tables: Table 1 identifies conditions associated with high-risk progression to severe COVID-19, while Table 2 outlines additional risk factors conferring increased vulnerability. Patients qualify as "high risk" if they possess either one high-risk factor or multiple factors associated with increased but non-high risk. Those lacking high-risk conditions are classified as having no significant progression risk. This risk stratification framework, informed by Omicron-era cohort data, recognizes that progression risk exists on a continuum influenced by factor severity and degree of immunosuppression. The guidelines ensure therapeutic agents are deployed according to their studied protocols and FDA Emergency Use Authorization requirements, providing healthcare providers with evidence-based decision-making tools for optimal patient outcomes.

The article examines vaccine confidence as a critical public health responsibility, prompted by a tragic case in Palermo in August 2026 when a four-year-old girl died of diphtheria, the first fatal case in Italy in over thirty years. Her family had refused vaccination based on the false belief that vaccines cause autism, despite the disease being legally mandatory in Italy. Meanwhile, her vaccinated cousin contracted the same infection but experienced only mild disease. While individual parental decisions contributed to this outcome, the article argues that public health institutions bear shared responsibility for vaccine confidence. The piece critiques the dominant "vaccine hesitancy" framework, which has dominated discussions for two decades, defined by WHO's Strategic Advisory Group of Experts as delay or refusal of vaccination despite service availability. Although frameworks like WHO's Behavioral and Social Drivers of Vaccination model and the 5C model have improved understanding of vaccination determinants, the discredited autism-vaccine claim continues influencing decisions. The article emphasizes that protecting vaccine confidence represents a core public health function extending beyond individual choice to encompassing institutional accountability and systematic approaches to address vaccination uncertainty.

The NIH RECOVER Initiative, a $1.15 billion federal research program, has achieved significant breakthroughs in understanding Long COVID's biological mechanisms, moving beyond symptom documentation to identifying treatable causes. Published findings in Nature Immunology reveal that Long COVID involves T-cell exhaustion driven by chronic activation of JAK-STAT and IL-6 pathways, causing persistent inflammation and immune dysfunction that leaves patients vulnerable to secondary infections and post-exertion crashes. Using the Digital Slide Archive, researchers discovered viral remnants—specifically nucleocapsid protein—persisting in gut and lymphatic tissues months post-infection, establishing viral persistence as a treatment target. The RECOVER-AUTONOMIC trial findings presented at the American College of Cardiology demonstrated that while Ivabradine reduced heart rates in POTS-affected patients, coordinated care combining medication with specialized diet, salt supplementation, and physical therapy produced superior outcomes. Crucially, research indicates exhaustion is imprinted on progenitor cells, creating "exhaustion memory" that affects newly generated immune cells. These discoveries represent a fundamental shift toward targeted, protocol-based treatments offering genuine hope for millions suffering from post-acute sequelae of SARS-CoV-2.

Long COVID, defined by the WHO as health problems persisting three or more months after SARS-CoV-2 infection, affects approximately 10-30 percent of non-hospitalised COVID cases and can develop regardless of initial infection severity. The condition shares striking biological and symptomatic overlap with ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome), a serious long-term multisystem illness documented since the 1950s. Many Long COVID patients meet clinical criteria for ME/CFS, experiencing shared features including Post-Exertional Malaise (PEM), cognitive dysfunction, orthostatic intolerance, immune abnormalities, and sleep disruption. Risk factors for Long COVID include female sex, older age, pre-existing conditions, and more severe initial illness, though the condition affects all ages and vaccinated individuals are not immune. Long COVID's emergence has reinvigorated scientific attention toward ME/CFS research, as patients developing either condition often present clinically indistinguishable presentations. Understanding this convergence is crucial for healthcare providers and researchers seeking to comprehend post-viral sequelae and develop effective management strategies for these debilitating conditions.

UCLA is conducting multiple clinical trials in Los Angeles for 2026 addressing COVID-19 and its complications. The baricitinib trial, open to adults 18 and older, investigates whether this JAK inhibitor improves neurocognitive and physical function, quality of life, and reduces post-exertional malaise in Long COVID patients, while measuring inflammatory biomarkers. A second trial tests investigational booster vaccines CoTend-s3BXBB and CoTend-BXBB in healthy volunteers aged 40-64, comparing five different doses to evaluate safety and whether the "s3" component enhances immune response breadth and duration through saliva, nasal, and blood sample analysis. A third trial, currently in progress, examined nirmatrelvir/ritonavir's safety and efficacy in treating non-hospitalized COVID-19 patients under 18 at risk for severe disease. Additionally, UCLA is developing a predictive test using clinical and molecular data from hospitalized patients to identify those at increased risk of adverse COVID-19 outcomes. These trials represent comprehensive efforts to address acute COVID-19 treatment, long-term complications, vaccine optimization, and patient risk stratification.

A representative survey of New York City residents examined the prevalence and functional impact of post-exertional malaise (PEM) among adults with prior COVID-19 infection. Post-exertional malaise is a debilitating condition characterized by symptom exacerbation following physical or cognitive exertion, and represents a significant concern for long COVID populations. The study assessed how PEM affects daily functioning and quality of life in COVID-19 survivors. The findings provide epidemiological data on the proportion of previously infected individuals experiencing PEM and document the functional consequences of this condition on work capacity, social engagement, and overall well-being. Understanding the prevalence and impact of post-exertional malaise in COVID-19 survivors is critical for healthcare providers, public health officials, and policymakers seeking to develop appropriate clinical management strategies and support systems for affected populations. This research contributes to the growing body of evidence characterizing long COVID sequelae and their burden on individuals and healthcare systems.

Long Covid, a condition characterized by symptoms persisting beyond two months following SARS-CoV-2 infection, has emerged as a significant public health concern since the end of the first pandemic wave in May 2020. The World Health Organization defines post-Covid-19 condition as occurring in individuals with probable or confirmed SARS-CoV-2 infection, with symptoms lasting at least two months that cannot be attributed to alternative diagnoses and generally appear within three months of initial infection. The United States employs a broader definition, encompassing all chronic health conditions occurring after SARS-CoV-2 infection lasting at least three months, including conditions potentially triggered by the virus such as diabetes and interstitial lung disease. By the end of 2022, approximately two million people in France were affected by long Covid, though precise prevalence estimates remain challenging due to varying definitional criteria and difficulties distinguishing between probable and confirmed infections. Understanding long Covid's impact is critical for healthcare systems and policymakers addressing the substantial burden this condition places on affected populations and healthcare resources.

Since the emergence of SARS-CoV-2 in late 2019, over 680 million cases and 6 million deaths have been recorded globally, with the United States accounting for over 100 million cases and 1 million deaths. While vaccines and therapeutics have reduced mortality in developed nations, millions of survivors experience Long COVID (LC), a post-acute infection syndrome characterized by persistent neurocognitive impairments and cardiopulmonary symptoms including dyspnea and exercise intolerance lasting months to years. Approximately 18 million American adults suffer from LC, with up to one in five previously employed patients unable to return to work due to cognitive and physical impairments. The public health burden represents the largest emerging disease impact in a century. Objective evidence shows Long COVID causes lasting cognitive dysfunction and structural brain changes, alongside activity-limiting fatigue, reduced exercise capacity, and diminished quality of life. Current hypotheses attribute Long COVID to viral reservoirs and systemic inflammation, yet no trials have investigated agents targeting these mechanisms. This randomized, double-blind, placebo-controlled trial addresses this critical gap, potentially offering the first effective therapeutic intervention for this devastating condition affecting millions worldwide.

The U.S. Food and Drug Administration has approved four updated COVID-19 vaccines for the 2026–2027 respiratory season, with manufacturers including Pfizer, Moderna, and Novavax beginning distribution immediately. All four vaccines—Comirnaty (Pfizer/BioNTech), Spikevax (Moderna), mNEXSPIKE (Moderna's lower-dose formulation), and Nuvaxovid (Novavax/Sanofi)—target the XFG variant selected by the FDA to better match circulating strains. Eligibility varies by vaccine but generally includes adults 65 and older and younger individuals with significant health conditions. The mRNA-based vaccines from Pfizer and Moderna work by providing temporary genetic instructions for spike protein production, while Novavax's protein-based alternative offers a non-mRNA option. Common side effects include injection-site pain, fatigue, and fever, with rare myocarditis cases predominantly affecting young males. As COVID-19 activity increases across the country heading into summer, infectious disease experts emphasize the updated vaccines' value in matching current circulating strains, though timing challenges delay immediate availability during the seasonal surge.

Researchers are increasingly investigating the connection between autoimmune diseases and conditions like postural orthostatic tachycardia syndrome (POTS) and long COVID, seeking to develop more targeted treatments. The case of physician Sarah Schafer, who developed POTS symptoms including lightheadedness, fatigue, and brain fog before being diagnosed with Sjögren's disease, an autoimmune disorder, exemplifies this emerging pattern. Evidence demonstrates that approximately one in five POTS patients are diagnosed with autoimmune diseases such as lupus or Hashimoto's, either before or after POTS onset, while autoimmune patients frequently develop nervous system dysfunction. This bidirectional relationship extends to infection-associated chronic conditions including long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), all triggered by immune system insults such as viral infections, pregnancy, or major injuries. Dr. Blair Grubb, a cardiologist at University of Toledo Health with nearly four decades of POTS patient experience, identifies specific "index events" as illness triggers. Understanding these autoimmune-dysautonomia connections could reveal shared underlying mechanisms and enable precision medicine approaches, potentially improving outcomes for millions affected by these debilitating conditions.

Pfizer and BioNTech announced U.S. FDA approval for COMIRNATY XFG, their 2026-2027 COVID-19 vaccine formula adapted to target the XFG variant. The supplemental Biologics License Application approval authorizes use in adults aged 65 and older, as well as individuals aged 5-64 with underlying conditions conferring high risk for severe COVID-19 outcomes. The FDA's decision was based on comprehensive clinical, non-clinical, and real-world evidence demonstrating that the XFG-adapted vaccine generates robust immune responses against currently circulating SARS-CoV-2 variants, including XFG, XFG.1.1, NB.1.8.1, PQ.17, and PQ.2.8.1. The XFG composition aligns with FDA guidance for the preferred vaccine composition beginning fall 2026. With over five billion COMIRNATY doses distributed globally to date, the vaccine continues demonstrating favorable safety and efficacy profiles. Doses will ship immediately and be available across U.S. pharmacies, hospitals, and clinics within days, leveraging BioNTech's proprietary mRNA technology platform.

The University of California Health is conducting multiple COVID-19 clinical trials in 2026 targeting specific patient populations across its medical centers. At UCSF, researchers are testing Anktiva, an investigational therapy, in patients aged 18-70 with Long COVID, administering up to two doses with comprehensive follow-up assessments. UC Davis is enrolling immunocompromised patients with lower tract parainfluenza infection and operating a sub-study for severe COVID-19 cases. At UCLA and UCSF, a baricitinib trial is examining whether this JAK inhibitor improves neurocognitive and physical function, quality of life, post-exertional malaise, and inflammatory biomarkers in Long COVID patients aged 18 and older compared to placebo. Additionally, an NIH-funded cooperative investigation involving UCI, Northwestern University, and USC is launching the REACH study for children and adolescents aged 10-17 with chronic conditions like cystic fibrosis and sickle cell disease. This project aims to revamp exercise assessment protocols for children with disabilities, addressing the critical gap in understanding safe physical activity levels when underlying medical conditions impose physiological constraints. These trials collectively represent significant efforts to address post-COVID sequelae and improve health outcomes for vulnerable populations.

UCSF is conducting multiple COVID-19 clinical trials in the San Francisco Bay Area to address Long COVID and develop improved vaccines. The trials include testing Anktiva, a therapeutic candidate for Long COVID safety and tolerability in patients ages 18-70, and baricitinib, a JAK inhibitor being evaluated against placebo to improve neurocognitive function, physical function, quality of life, post-exertional malaise, and inflammation markers in Long COVID patients. Advanced imaging studies utilize [18F]F-AraG PET-CT imaging to investigate immune activation and vascular changes in post-acute sequelae of SARS-CoV-2 infection, enrolling up to 80 participants over 48 months. These imaging studies aim to characterize tissue-level immune dysregulation and correlate findings with blood biomarkers and symptom patterns to support future clinical assessment tools. Additionally, UCSF is testing two investigational COVID-19 booster vaccines—CoTend-s3BXBB and CoTend-BXBB—in healthy volunteers ages 40-64. The CoTend-s3BXBB variant includes an "s3" component designed to enhance immune response. These trials represent comprehensive efforts to understand Long COVID pathophysiology and develop effective therapeutic and preventive interventions for COVID-related conditions.

This retrospective cohort study examined 395 hospitalized COVID-19 patients admitted between December 2022 and March 2023 to investigate how sex and age influence disease severity and immune responses. Researchers from Xi'an's Ninth Hospital analyzed 45 biomarkers related to multi-organ injury and immune function using statistical methods including the Mann-Whitney U test and multivariable logistic regression with Benjamini-Hochberg false discovery rate correction. The findings revealed that 76% of severe cases occurred in male patients, while those aged 75 years or older represented 79% of severe cases. After false discovery rate correction, 37 of 45 biomarkers differed significantly by severity, with males demonstrating elevated inflammatory, coagulation, cardiac, hepatic, and renal injury markers alongside lower lymphocyte counts and nutritional reserves. Older male patients exhibited the most pronounced inflammatory responses and multi-organ dysfunction. Multivariable analysis confirmed male sex increased severe COVID-19 risk 1.9-fold, while age 75 years or older increased risk 5.2-fold. These findings underscore that biological sex and advanced age are independent risk factors for severe COVID-19, likely mediated through multi-organ dysfunction and immunosuppression following SARS-CoV-2 infection, with important implications for risk stratification and targeted therapeutic interventions.